UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease

Journal of Neurochemistry

Volumn 90, Issue 2, 2004, Pages 379-391

  Ardley, Helen C ^a,b   Scott, Gina B ^a   Rose, Stephen A ^a   Tan, Nancy G S ^a   Robinson, Philip A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

De ubiquitylating enzyme; Inclusion bodies; Neurodegeneration; Parkinson's disease; Ubiquitin

Indexed keywords

ALPHA SYNUCLEIN; CHAPERONE; GAMMA TUBULIN; GREEN FLUORESCENT PROTEIN; HEAT SHOCK PROTEIN 70; PARKIN; PROTEASOME; PROTEIN UCH L1; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

AGGRESOME; ANIMAL CELL; ARTICLE; CELL INCLUSION; CELL LYSATE; CELL STRAIN COS7; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; LEWY BODY; NERVE DEGENERATION; NEUROBLASTOMA CELL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; UBIQUITINATION;

ALPHA-SYNUCLEIN; ANIMALS; CARRIER PROTEINS; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; CYSTEINE ENDOPEPTIDASES; ENZYME INHIBITORS; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INCLUSION BODIES; LEWY BODIES; MACROMOLECULAR SUBSTANCES; MOLECULAR CHAPERONES; MULTIENZYME COMPLEXES; MUTAGENESIS, SITE-DIRECTED; MUTATION; NERVE TISSUE PROTEINS; NEURONS; PARKINSON DISEASE; PRECIPITIN TESTS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECOMBINANT FUSION PROTEINS; SOLUBILITY; SYNUCLEINS; TRANSFECTION; TUBULIN; UBIQUITIN; UBIQUITIN THIOLESTERASE; UBIQUITIN-PROTEIN LIGASES;

ANIMALIA;

EID: 3142724742     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02485.x     Document Type: Article

References (72)

1. Apostol B. L., Kazantsev A., Raffioni S. et al. (2003) A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc. Natl Acad. Sci. USA 100, 5950-5955.
2. Ardley H. C., Tan N. G. S., Rose S. A., Markham A. F. and Robinson P. A. (2001) Features of the Parkin/Ariadne-like ubiquitin ligase, HHARI, that regulate its interaction with the ubiquitin-conjugating enzyme, UbcH7. J. Biol. Chem. 276, 19640-19647.
3. Ardley H. C., Scott G. B., Rose S. A., Tan N. G. S., Markham A. F. and Robinson P. A. (2003) Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. Mol. Biol. Cell 14, 4541-4556.
4. Askham J. M., Moncur P., Markham A. F. and Morrison E. E. (2000) Regulation and function of the interaction between the APC tumour suppressor protein and EB1. Oncogene 19, 1950-1958.
5. Baek K. H., Kim M. S., Kim Y. S., Shin J. M. and Choi H. K. (2004) DUB-1A, a novel deubiquitinating enzyme subfamily member, is polyubiquitinated and cytokine-inducible in B-lymphocytes. J. Biol. Chem. 279, 2368-2376.
6. Burnett B., Li F. and Pittman R. M. (2003) The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum. Mol. Genet. 12, 3195-3205.
7. Bush K. T., Goldberg A. L. and Nigam S. K. (1997) Proteasome inhibition leads to heat-shock response, induction of endoplasmic reticulum chaperones and thermotolerance. J. Biol. Chem. 272, 9086-9092.
8. Choi P., Golts N., Snyder H., Chong M., Petrucelli L., Hardy J., Sparkman D., Cochran E., Lee J. M. and Wolozin B. (2001) Co association of Parkin and alpha-synuclein. Neuroreport 12, 2839-2843.
9. Chung C. H. and Baek S. H. (1999) Deubiquitinating enzymes: Their diversity and emerging roles. Biochem. Biophys. Res. Commun. 266, 633-640.
10. Cookson M. R., Lockhart P. J., McLendon C., O'Farrell C., Schlossmacher M. and Farrer M. J. (2003) RING finger 1 mutations in Parkin produce altered localization of the protein. Hum. Mol. Genet. 12, 2957-2965.
11. Cummings C. J., Reinstein E., Sun Y., Antalffy B., Jiang Y., Ciechanover A., Orr H. T., Beaudet A. L. and Zoghbi H. Y. (1999) Mutation in the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating poly-glutamine induced pathology in SCA1 mice. Neuron 24, 879-892.
12. Davies S. W., Turmaine M., Cozens B. A., DiFiglia M., Sharp A. H., Ross C. A., Scherzinger E., Wanker E. E., Mangiarini L. and Bates G. P. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548.
13. Dekker M. C. J., Bonifati V. and van Duijn C. M. (2003) Parkinson's disease: piecing together a genetic jigsaw. Brain 126, 1722-1733.
14. DiFiglia M., Sapp E., Chase K. O., Davies S. W., Bates G. P., Vonsattel J. P. and Aronin N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993.
15. Doherty F. J., Dawson S. and Mayer R. J. (2002) The ubiquitin-proteasome pathway of intracellular proteolysis. Essays Biochem. 38, 51-63.
16. Elbaz A., Levecque C., Clavel J. et al. (2003) S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: Evidence for an age-dependent relationship. Mov. Disord. 18, 130-137.
17. Fujimuro M., Sawada H. and Yokosawa H. (1994) Production and characterisation of monoclonal antibodies specific to multi-ubiquitin chains of polyubiquitinated proteins. FEBS Lett. 349, 173-180.
18. Garcia-Mata R., Bebok Z., Sorscher E. J. and Sztul E. S. (1999) Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J. Cell Biol. 146, 1239-1254.
19. Garcia-Mata R., Gao Y.-S. and Sztul E. (2002) Hassles of taking out the garbage: Aggravating aggresomes. Traffic 3, 388-396.
20. Goto S., Takahashi R., Kumiyama A., Radak Z., Hayashi T., Takenouchi M. and Abe R. (2001) Implications of protein degradation in aging. Ann. N.Y. Acad. Sci. 928, 54-64.
21. Hampshire D. J., Roberts E., Crow Y., Bond J., Mubaidin A., Wriekat A.-L., Al-Din A. and Woods C. G. (2001) Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36. J. Med. Genet. 38, 680-682.
22. Hibi K., Westra W. H., Borges M., Goodman S., Sidransky D. and Jen J. (1999) PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am. J. Pathol. 155, 711-715.
23. Huang Y., Baker R. T. and Fischer-Vize J. A. (1995) Control of cell fate by a deubiquitinating enzyme encoded by the fat facets gene. Science 270, 1828-1831.
24. Ii K., Ito H., Tanaka K. and Hirano A. (1997) Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J. Neuropathol. Exp. Neurol. 56, 125-131.
25. Johnston J. A., Ward C. L. and Kopito R. R. (1998) Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 143, 1883-1898.
26. Junn E., Lee S. S., Suhr U. T. and Mouradian M. M. (2002) Parkin accumulation in aggresomes due to proteasome impairment. J. Biol. Chem. 277, 47870-47877.
27. Kaytor M. D. and Warren S. T. (1999) Aberrant protein deposition and neurological disease. J. Biol. Chem. 274, 7507-37510.
28. Kisselev A. F. and Goldberg A. L. (2001) Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8, 739-758.
29. Kuznetsov G., Bush K. T., Zhang P. L. and Nigam S. K. (1996) Perturbations in maturation of secretory proteins and their association with endoplasmic reticulum chaperones in a cell culture model for epithelial ischemia. Proc. Natl Acad. Sci. USA 93, 8584-8589.
30. Lang A. E. and Lozano A. M. (1998) Parkinson's disease. First of two parts. N. Engl. J. Med. 339, 1044-1053.
31. Lee D. H. and Goldberg A. L. (1998) Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8, 397-403.
32. Lee H.-J., Shin S. Y., Choi C., Lee Y. H. and Lee S.-J. (2002) Formation and removal of α-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 277, 5411-5417.
33. Leroy E., Boyer R., Auburger G. et al. (1998) The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452.
34. Liu Y., Fallon L., Lashuel H. A., Liu Z. and Lansbury P. T. Jr (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111, 209-218.
35. Lowe J., Blanchard A., Morrell K., Lennox G., Reynolds L., Billett M., Landon M. and Mayer R. J. (1988) Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease. J. Pathol. 155, 9-15.
36. Lowe J., McDermontt H., Landon M., Mayer R. J. and Wilkinson K. D. (1990) Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of neurodegenerative diseases. J. Pathol. 161, 153-160.
37. Maraganore D. M., de Andrade M., Lesnick T. G., Farrer M. J., Bower J. H., Hardy J. A. and Rocca W. A. (1999) Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 53, 1858-1860.
38. McNaught K. St P. and Jenner P. (2001) Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297, 191-194.
39. McNaught K. St P. and Olanow C. W. (2003) Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann. Neurol. 53, S73-S86.
40. McNaught K. St P., Olanow C. W., Halliwell B., Isacson O. and Jenner P. (2001) Failure of the ubliquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2, 589-594.
41. McNaught K. S. P., Belizaire R., Jenner P., Olanow C. W. and Isacson O. (2002a) Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci. Lett. 326, 155-158.
42. McNaught K. St P., Shashidharan P., Perl D. P., Jenner P. and Olanow C. W. (2002b) Aggresome-related biogenesis of Lewy bodies. Euro. J. Neurosci. 16, 2136-2148.
43. McNaught K. St P., Belizaire R., Isacson O., Jenner P. and Olanow C. W. (2003) Altered proteasome function in sporadic Parkinson's disease. Exp. Neurol. 179, 38-46.
44. Meriin A. B., Mabuchi K., Gabai V. L., Yaglom J. A., Kazantsev A. and Sherman M. Y. (2001) Intracellular aggregation of polypeptides with expanded polyglutamine domain is stimulated by stress-activated kinase MEKK1. J. Cell Biol. 153, 851-864.
45. Miller D. W., Ahmad R., Hague S. et al. (2003) L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J. Biol. Chem. 278, 36588-36595.
46. Muqit M. M. K., Davidson S. M., Payne Smith M. D., MacCormac L. P., Kahns S., Jensen P. H., Wood N. W. and Latchman D. S. (2004) Parkin is recruited into aggresomes in a stress specific manner: over-expression of parkin reduces aggresome formation but can be dissociated from parkin's effect on neuronal survival. Hum. Mol. Genet. 13, 117-135.
47. Naze P., Vuillaume I., Destee A., Pasquier F. and Sabloniere B. (2002) Mutation analysis and association of the ubiquitin carboxy-terminal hydrolase L1 gene: in Huntington's disease. Neurosci. Lett. 328, 1-4.
48. Nishikawa K., Li H., Kawamura R. et al. (2003) Alterations of structure and hydrolase activity of Parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem. Biophys. Res. Comm. 304, 176-183.
49. Osaka H., Wang Y. L., Takada K. et al. (2003) Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum. Mol. Genet. 12, 1945-1958.
50. Pickart C. M. (2001) Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503-533.
51. Pollen M. S., Dickson D. W. and Bergeron C. (1993) Pathology of the Lewy body. J. Neuropathol. Exp. Neurol. 52, 183-191.
52. Rideout H. J., Larsen K. E. Sulzer D. and Stefanis L. (2001) Proteasomal inhibition leads to formation of ubiquitin/α-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem. 78, 899-908.
53. Saudou F., Finkbeiner S., Devys D. and Greenberg M. E. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66.
54. Schlossmacher M. G., Frosch M. P., Gai W. P. et al. (2002) Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am. J. Pathol. 160, 1655-1667.
55. Serwold T., Gonzalez F., Kim J., Jacob R. and Shastri N. (2002) ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 419, 480-483.
56. Sherman M. Y. and Goldberg A. L. (2001) Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29, 15-32.
57. Shimura H., Hattori N., Kubo S. et al. (1999) Immunohistochemical and subcellular localization of Parkin protein: Absence of protein in amosomal recessive juvenile Parkinsonism patients. Ann. Neurol. 45, 668-672.
58. Shimura H., Hattori N., Kubo S. et al. (2000) Familial Parkinson disease gene product, Parkin, is a ubiquitin-protein ligase. Nature Genet. 25, 302-305.
59. Shimura H., Schlossmacher M. G., Hattori N., Frosch M. P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K. S. and Selkoe D. J. (2001) Ubiquitination of a new form of α-synuclein by Parkin from human brain: Implications for Parkinson's disease. Science 293, 263-269.
60. Spillantini M. G., Schmidt G., Lee V. M. Y., Trojanowski J. Q., Jakes M. and Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
61. Takase T., Hibi K., Yamazaki T., Nakayama H., Taguchi M., Kasai Y., Ito K., Akiyama S., Nagasaka T. and Nakao A. (2003) PGP9.5 overexpression in esophageal squamous cell carcinoma. Hepatogastroenterology 50, 1278-1280.
62. Tanaka M., Kim Y. M., Lee G., Junn E., Iwatsubo T. and Mouradian M. M. (2004) Aggresomes formed by α-Synuclein and Synphilin-1 are cytoprotective. J. Biol. Chem. 279, 4625-4631.
63. Tian Q. B., Okano A., Nakayama K., Miyazawa S., Endo S. and Suzuki T. (2003) A novel ubiquitin-specific protease, synUSP, is localised at the post-synaptic density and post-synaptic lipid raft. J. Neurochem. 87, 665-675.
64. Tofaris G. K., Razzaq A., Ghetti B., Lilley K. S. and Spillantini M. G. (2003) Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 278, 44405-44411.
65. Tsubuki S., Saito Y., Tomioka M., Ito H. and Kawashima S. (1996) Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J. Biochem. 119, 572-576.
66. Valente E. M., Bentivoglio A. R., Dixon P. H., Ferraris A., Ialongo T., Frontali M., Albanese A. and Wood N. W. (2001) Localization of a novel locus for autosomal recessive early-onset Parkinsonism, PARK6, on human chromosome lp35-p36. Am. J. Hum. Genet. 68, 895-900.
67. Waelter S., Boeddrich A., Lurz R., Scherzinger E., Lueder G., Lehrach H. and Wanker E. E. (2001) Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol. Biol. Cell 12, 1393-1407.
68. Weissman A. M. (2001) Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol. 2, 169-178.
69. Wilkinson K. D., Lee K. M., Deshpande S., Duerksen-Hughes P., Boss J. M. and Pohl J. (1989) The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246, 670-673.
70. Yamazaki T., Hibi K., Takase T., Tezel E., Nakayama H., Kasai Y., Ito K., Akiyama S., Nagasaka T. and Nakao A. (2002) PGP9.5 as a marker for invasive colorectal cancer. Clin. Cancer Res. 8, 192-195.
71. Zhang J., Hattori N., Leroy E., Morris H. R., Kubo S.-I., Kobayashi T. M., Wood N. W., Polymeropoulos M. H. and Mizuno Y. (2000a) Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. Parkinsonism. Relat. Disord. 6, 195-197.
72. Zhang J., Hattori N., Giladi N. and Mizuno Y. (2000b) Failure to find mutations in ubiquitin carboxy-terminal hydrolase L1 gene in familial Parkinson's disease. Parkinsonism Relat. Disord. 6, 199-200.